Biota partner to market
Monday, 30 March, 2009
Japanese biopharma Daiichi Sankyo, which co-owns a long-acting neuraminidase inhibitor for influenza with Australia’s Biota, has applied to manufacture and market the drug in Japan.
The contract depends on the successful completion of Phase III trials in Asia and on obtaining regulatory approval.
The trials have completed patient enrolment with results expected mid-year, Biota said in a statement.
The drug, CS-8958, is a long-acting flu drug which needs less frequent dosing than current neuraminidase inhibitors such as Roche’s oseltamivir (Tamiflu) and Biota’s own zanamivir (Relenza), which is marketed by GSK.
Daiichi Sankyo has rights to the drug in Japan, but Biota said all other key markets are available for licensing by the partners.
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
Newborns have elevated levels of an Alzheimer's biomarker
What do the brains of newborns and patients with Alzheimer's disease have in common? Both...
